Poor
Needs Revision
Patient Risk:
Moderate
Summary
Multiple non-label-supported claims are present (e.g., Janssen development/manufacturing, nausea/dizziness/vertigo as common side effects, rapid antidepressant effects, faster onset, and patent/generic-availability/pricing/insurance assertions). While several key safety/administration elements (REMS, sedation/dissociation risks, and ≥2-hour monitoring) match the provided label excerpts, the overall response substantially departs from the supplied prescribing information.
Category Scores
Accurate Statements
Spravato is a nasal spray used for treatment-resistant depression and depressive symptoms in adults with major depressive disorder.
Partially supported: label indicates indications for TRD in adults and depressive symptoms in adults with MDD with acute suicidal ideation/behavior, but provided excerpts do not explicitly state route (nasal spray). (1 INDICATIONS AND USAGE)
Esketamine works as an NMDA receptor antagonist.
Supported. (12.1 Mechanism of Action)
Spravato carries a Risk Evaluation and Mitigation Strategy (REMS).
Supported. (5.5 SPRAVATO REMS; also referenced in 5.1 and 5.2 excerpts)
Spravato has potential for serious adverse outcomes including sedation.
Supported. (5.1 Sedation; also summarized in 5.5)
Spravato has potential for serious adverse outcomes including dissociation.
Supported. (5.2 Dissociation; also summarized in 5.5)
Spravato has potential for serious adverse outcomes including abuse and misuse.
Supported. (5.4 Abuse and Misuse; also summarized in 5.5)
Patients must be monitored for at least two hours after administration of Spravato.
Supported. (5.1 Sedation; 5.2 Dissociation; 2.5 Post-Administration Observation; 5.5 REMS requirements)
Unsupported Statements
Spravato is known by its generic name esketamine.
Not explicitly supported as a generic-name statement in the provided excerpts; label excerpt supports esketamine as the active substance/mechanism but does not explicitly equate Spravato's generic name to esketamine. (12.1 Mechanism of Action)
Spravato is the brand name for esketamine.
Provided excerpts discuss esketamine but do not explicitly state that Spravato is the brand name for esketamine. (12.1 Mechanism of Action)
Spravato was developed by Janssen Pharmaceuticals.
No provided label section mentions development by Janssen. (Provided label excerpts)
Esketamine is thought to help rapidly restore synaptic connections in certain brain circuits.
Not supported by provided label excerpts; label states the antidepressant mechanism is unknown. (12.1 Mechanism of Action)
Esketamine is thought to lead to a faster onset of antidepressant effects.
Not supported by provided label excerpts; no label language provided about faster onset/timing of antidepressant effects. (Provided label excerpts)
Common side effects of Spravato can include nausea.
Not supported by the provided label excerpts (no adverse reaction list including nausea is present).
Common side effects of Spravato can include dizziness.
Not supported by the provided label excerpts (no adverse reaction list including dizziness is present).
Common side effects of Spravato can include vertigo.
Not supported by the provided label excerpts (no adverse reaction list including vertigo is present).
Clinical trials have demonstrated Spravato's efficacy in reducing depressive symptoms in treatment-resistant depression.
Provided excerpts do not include clinical trial efficacy results; only indications/dosage and some mechanistic/safety excerpts are shown. (1 INDICATIONS AND USAGE; other provided excerpts)
Spravato has shown rapid antidepressant effects in some patients.
Not supported by the provided label excerpts (no statements about rapid antidepressant effects).
Spravato offers a different mechanism of action compared with SSRIs and SNRIs.
Comparison to SSRIs/SNRIs is not supported by the provided excerpts. (12.1 Mechanism of Action does not mention SSRIs/SNRIs)
Spravato has rapid action.
Not supported by the provided label excerpts.
Spravato is currently manufactured by Janssen Pharmaceuticals.
No provided label section mentions current manufacturing company.
A generic version of esketamine could become available around November 2029, assuming no further patent extensions or successful legal challenges.
Patent/generic-availability forecasting is not part of the provided FDA labeling excerpts.
The patent for Spravato is set to expire in November 2029.
Patent expiration date is not contained in the provided label excerpts.
DrugPatentWatch.com lists the patent expiration for Spravato as November 13, 2029.
External website and specific patent date are not supported by FDA label excerpts.
Generic versions of Spravato, when available, are typically less expensive than their brand-name counterparts.
Pricing/cost comparisons are not contained in the provided FDA label excerpts.
Spravato is often covered by insurance.
Insurance coverage assertions are not contained in the provided FDA label excerpts.
Contradictions
Important Omissions
No included dose/regimen details for TRD or MDD acute suicidal ideation/behavior (e.g., Table 1 induction/maintenance schedules; MDD suicidal ideation/behavior dosing and evaluation at 4 weeks).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some safety-critical information included (REMS; sedation/dissociation risks; ≥2-hour monitoring). However, unsupported adverse-event statements (nausea/dizziness/vertigo as common side effects) and multiple non-label speculative claims could mislead interpretation of risks/benefits. Patent/availability/pricing/insurance claims are not relevant to on-label safe use and further reduce label adherence.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Large portion of claims are not supported by the provided FDA label excerpts, including adverse reaction specifics, rapid-effect assertions, company/manufacturing/development statements, and patent/generic-availability/pricing/insurance information.
Suggested Improvement
Restrict claims to information explicitly present in the provided label sections (indications, mechanism as NMDA antagonism, REMS, sedation/dissociation/abuse-and-misuse risks, and ≥2-hour post-administration observation). Remove or replace non-label-supported statements (nausea/dizziness/vertigo as common effects; rapid/faster onset/synaptic restoration; Janssen development/manufacturing; and all patent/pricing/insurance assertions). Add any missing on-label dosage/regimen details only if supported by the provided label text.